1921 related articles for article (PubMed ID: 16805772)
1. The chemical biology of clinically tolerated NMDA receptor antagonists.
Chen HS; Lipton SA
J Neurochem; 2006 Jun; 97(6):1611-26. PubMed ID: 16805772
[TBL] [Abstract][Full Text] [Related]
2. Inflammatory mediators leading to protein misfolding and uncompetitive/fast off-rate drug therapy for neurodegenerative disorders.
Lipton SA; Gu Z; Nakamura T
Int Rev Neurobiol; 2007; 82():1-27. PubMed ID: 17678953
[TBL] [Abstract][Full Text] [Related]
3. Psychotogenicity and N-methyl-D-aspartate receptor antagonism: implications for neuroprotective pharmacotherapy.
Kornhuber J; Weller M
Biol Psychiatry; 1997 Jan; 41(2):135-44. PubMed ID: 9018383
[TBL] [Abstract][Full Text] [Related]
4. The molecular basis of memantine action in Alzheimer's disease and other neurologic disorders: low-affinity, uncompetitive antagonism.
Lipton SA
Curr Alzheimer Res; 2005 Apr; 2(2):155-65. PubMed ID: 15974913
[TBL] [Abstract][Full Text] [Related]
5. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
Lipton SA
J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
[TBL] [Abstract][Full Text] [Related]
6. Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation.
Lipton SA
Curr Drug Targets; 2007 May; 8(5):621-32. PubMed ID: 17504105
[TBL] [Abstract][Full Text] [Related]
7. Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond.
Lipton SA
Nat Rev Drug Discov; 2006 Feb; 5(2):160-70. PubMed ID: 16424917
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic N-methyl-D-aspartate receptor antagonists: will reality meet expectation?
Smith PF
Curr Opin Investig Drugs; 2003 Jul; 4(7):826-32. PubMed ID: 14619404
[TBL] [Abstract][Full Text] [Related]
9. Targeting excitotoxic/free radical signaling pathways for therapeutic intervention in glaucoma.
Seki M; Lipton SA
Prog Brain Res; 2008; 173():495-510. PubMed ID: 18929130
[TBL] [Abstract][Full Text] [Related]
10. [Glutamate-related excitotoxicity neuroprotection with memantine, an uncompetitive antagonist of NMDA-glutamate receptor, in Alzheimer's disease and vascular dementia].
Tanović A; Alfaro V
Rev Neurol; 2006 May 16-31; 42(10):607-16. PubMed ID: 16703529
[TBL] [Abstract][Full Text] [Related]
11. Mechanism of action of memantine.
Johnson JW; Kotermanski SE
Curr Opin Pharmacol; 2006 Feb; 6(1):61-7. PubMed ID: 16368266
[TBL] [Abstract][Full Text] [Related]
12. [The N-methyl-D-aspartate receptor complex. Various sites of regulation and clinical consequences].
Turski L
Arzneimittelforschung; 1990 May; 40(5):511-4. PubMed ID: 1974426
[TBL] [Abstract][Full Text] [Related]
13. The NMDA receptor complex: a long and winding road to therapeutics.
Wood PL
IDrugs; 2005 Mar; 8(3):229-35. PubMed ID: 15772895
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of action of neuroprotectants in stroke.
Lyden P; Wahlgren NG
J Stroke Cerebrovasc Dis; 2000 Nov; 9(6 Pt 2):9-14. PubMed ID: 17895214
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological implications of two distinct mechanisms of interaction of memantine with N-methyl-D-aspartate-gated channels.
Chen HS; Lipton SA
J Pharmacol Exp Ther; 2005 Sep; 314(3):961-71. PubMed ID: 15901795
[TBL] [Abstract][Full Text] [Related]
16. Failures and successes of NMDA receptor antagonists: molecular basis for the use of open-channel blockers like memantine in the treatment of acute and chronic neurologic insults.
Lipton SA
NeuroRx; 2004 Jan; 1(1):101-10. PubMed ID: 15717010
[TBL] [Abstract][Full Text] [Related]
17. Amantadine and memantine are NMDA receptor antagonists with neuroprotective properties.
Kornhuber J; Weller M; Schoppmeyer K; Riederer P
J Neural Transm Suppl; 1994; 43():91-104. PubMed ID: 7884411
[TBL] [Abstract][Full Text] [Related]
18. Glycine binding primes NMDA receptor internalization.
Nong Y; Huang YQ; Ju W; Kalia LV; Ahmadian G; Wang YT; Salter MW
Nature; 2003 Mar; 422(6929):302-7. PubMed ID: 12646920
[TBL] [Abstract][Full Text] [Related]
19. Neuroprotective properties of memantine in different in vitro and in vivo models of excitotoxicity.
Volbracht C; van Beek J; Zhu C; Blomgren K; Leist M
Eur J Neurosci; 2006 May; 23(10):2611-22. PubMed ID: 16817864
[TBL] [Abstract][Full Text] [Related]
20. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence.
Danysz W; Parsons CG
Int J Geriatr Psychiatry; 2003 Sep; 18(Suppl 1):S23-32. PubMed ID: 12973747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
